Sanford C. Bernstein Cuts Guardant Health (NASDAQ:GH) Price Target to $35.00

Guardant Health (NASDAQ:GH) had its price objective reduced by Sanford C. Bernstein from $40.00 to $35.00 in a report released on Wednesday, Benzinga reports. They currently have an outperform rating on the stock.

Other research analysts have also recently issued reports about the company. UBS Group boosted their target price on Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, August 21st. TD Cowen boosted their target price on Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. boosted their target price on Guardant Health from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. BTIG Research boosted their target price on Guardant Health from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. Finally, Craig Hallum boosted their target price on Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $40.00.

Guardant Health Stock Up 5.9 %

Shares of Guardant Health stock opened at $23.07 on Wednesday. The company has a quick ratio of 6.07, a current ratio of 6.40 and a debt-to-equity ratio of 16.70. Guardant Health has a 12 month low of $15.81 and a 12 month high of $37.04. The business has a fifty day simple moving average of $23.49 and a 200 day simple moving average of $25.66. The stock has a market cap of $2.82 billion, a PE ratio of -5.89 and a beta of 1.11.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The company had revenue of $177.24 million for the quarter, compared to analyst estimates of $162.59 million. During the same period last year, the firm earned ($0.67) earnings per share. The firm’s revenue for the quarter was up 29.2% on a year-over-year basis. Research analysts predict that Guardant Health will post -3.31 EPS for the current year.

Institutional Trading of Guardant Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Duality Advisers LP bought a new stake in Guardant Health during the first quarter worth about $1,154,000. Swiss National Bank raised its stake in Guardant Health by 3.3% in the first quarter. Swiss National Bank now owns 227,700 shares of the company’s stock valued at $4,697,000 after buying an additional 7,300 shares during the period. Principal Financial Group Inc. raised its stake in Guardant Health by 1,649.4% in the first quarter. Principal Financial Group Inc. now owns 228,215 shares of the company’s stock valued at $4,708,000 after buying an additional 215,170 shares during the period. State Board of Administration of Florida Retirement System raised its stake in Guardant Health by 254.0% in the first quarter. State Board of Administration of Florida Retirement System now owns 114,125 shares of the company’s stock valued at $2,354,000 after buying an additional 81,887 shares during the period. Finally, First Light Asset Management LLC raised its stake in Guardant Health by 119.7% in the second quarter. First Light Asset Management LLC now owns 416,967 shares of the company’s stock valued at $12,042,000 after buying an additional 227,202 shares during the period. Institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.